{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:31:18Z","timestamp":1789749078545,"version":"4.0.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome is an ultra-rare, combined primary immunodeficiency and chronic neutropenic disorder characterized by a range of clinical presentations, including peripheral neutropenia, lymphopenia, and recurrent infections. WHIM syndrome is most often caused by gain-of-function mutations in the gene encoding C-X-C chemokine receptor 4 (CXCR4). As such, inhibition of CXCR4 with XOLREMDI<jats:sup>\u00ae<\/jats:sup> (mavorixafor), an orally bioavailable CXCR4 antagonist, demonstrated clinically meaningful increases in absolute neutrophil and lymphocyte counts and concomitant reduction in infections in patients with WHIM syndrome, resulting in its recent U.S. Food and Drug Administration approval. The impact of CXCR4 antagonism on other aspects of the pathobiology in WHIM syndrome, such as lymphopoiesis and leukocyte trafficking between primary and secondary lymphoid organs, is less understood.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In the current study, the effects of CXCR4 antagonism on leukocyte trafficking and distribution in primary and secondary lymphoid organs were investigated in a mouse model of WHIM syndrome carrying the heterozygous <jats:italic>Cxcr4<jats:sup>1013<\/jats:sup><\/jats:italic> mutation. <jats:italic>Cxcr4<jats:sup>+\/1013<\/jats:sup><\/jats:italic> and <jats:italic>Cxcr4<\/jats:italic> wild-type mice received the orally bioavailable CXCR4 antagonist X4-185. Blood, spleen and bone marrow samples were collected for numeration, flow cytometry, and functional studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p><jats:italic>Cxcr4<jats:sup>+\/1013<\/jats:sup><\/jats:italic> mice exhibited profound peripheral blood leukopenia as seen in patients with WHIM syndrome. CXCR4 antagonism corrected circulating leukopenia and mobilized functional neutrophils without disrupting granulopoiesis in the bone marrow of <jats:italic>Cxcr4<jats:sup>+\/1013<\/jats:sup><\/jats:italic> mice. Furthermore, <jats:italic>Cxcr4<jats:sup>+\/1013<\/jats:sup><\/jats:italic> displayed aberrant splenic T and B-cell counts and frequency. Treatment with X4-185 normalized splenic T-cell abnormalities, correcting the reduced CD8<jats:sup>+<\/jats:sup> T-cell numbers, restoring the CD4\/CD8 T-cell ratio, and ameliorating peripheral blood T-cell lymphopenia. In addition, CXCR4 antagonism was able to correct the abnormal frequencies and numbers of splenic marginal zone and follicular B cells in <jats:italic>Cxcr4<jats:sup>+\/1013<\/jats:sup><\/jats:italic> mice, and ultimately normalize B-cell lymphopenia in the peripheral circulation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our study provides comprehensive evidence that oral dosing with a CXCR4 antagonist can effectively correct WHIM-associated neutrophil and lymphocyte abnormalities in a mouse model of WHIM syndrome. These findings extend our understanding of how targeting the dysregulated CXCR4 signaling pathway can ameliorate the pathogenesis of WHIM syndrome.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1468823","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T06:10:26Z","timestamp":1731305426000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["CXCR4 antagonism ameliorates leukocyte abnormalities in a preclinical model of WHIM syndrome"],"prefix":"10.3389","volume":"15","author":[{"given":"Lilian","family":"Roland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Huu","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Zmajkovicova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Khamyath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kalogeraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9r\u00e9nice","family":"Schell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Gourhand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Rondeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeina","family":"Abou Nader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halenya","family":"Monticelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Maierhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Taveras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Esp\u00e9li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Balabanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2289","article-title":"WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12","volume":"105","author":"Balabanian","year":"2005","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01312-7","article-title":"Disease progression of WHIM syndrome in an international cohort of 66 pediatric and adult patients","volume":"42","author":"Geier","year":"2022","journal-title":"J Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-019-00665-w","article-title":"WHIM syndrome: from pathogenesis towards personalized medicine and cure","volume":"39","author":"Heusinkveld","year":"2019","journal-title":"J Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90187-i","article-title":"A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia","volume":"89","author":"Wetzler","year":"1990","journal-title":"Am J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e32831ac557","article-title":"WHIM syndrome: congenital immune deficiency disease","volume":"16","author":"Kawai","year":"2009","journal-title":"Curr Opin Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19373","article-title":"CXCR4 WHIM syndrome is a cancer predisposition condition for virus-induced Malignancies","volume":"204","author":"Moulin","year":"2024","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-395608","article-title":"WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4","volume":"120","author":"Liu","year":"2012","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10875-016-0276-3","article-title":"WHIM syndrome caused by waldenstrom\u2019s macroglobulinemia-associated mutation CXCR4 (L329fs)","volume":"36","author":"Liu","year":"2016","journal-title":"J Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/ng1149","article-title":"Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease","volume":"34","author":"Hernandez","year":"2003","journal-title":"Nat Genet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-7-71","article-title":"Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry","volume":"7","author":"Beaussant Cohen","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.imlet.2016.06.006","article-title":"CXCR4 signaling in health and disease","volume":"177","author":"Pozzobon","year":"2016","journal-title":"Immunol Lett"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e12949","DOI":"10.1111\/eci.12949","article-title":"CXCR4, the master regulator of neutrophil trafficking in homeostasis and disease","author":"De Filippo","year":"2018","journal-title":"Eur J Clin Invest"},{"key":"B13","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41435-022-00181-9","article-title":"Genotype-phenotype correlations in WHIM syndrome: a systematic characterization of CXCR4(WHIM) variants","volume":"23","author":"Zmajkovicova","year":"2022","journal-title":"Genes Immun"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/ijms20010003","article-title":"Adaptive immunodeficiency in WHIM syndrome","volume":"20","author":"Majumdar","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-403378","article-title":"Proper desensitization of CXCR4 is required for lymphocyte development and peripheral compartmentalization in mice","volume":"119","author":"Balabanian","year":"2012","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20160806","article-title":"Lymphoid differentiation of hematopoietic stem cells requires efficient Cxcr4 desensitization","volume":"214","author":"Freitas","year":"2017","journal-title":"J Exp Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"eabo3170","DOI":"10.1126\/sciimmunol.abo3170","article-title":"Dysregulated stem cell niches and altered lymphocyte recirculation cause B and T cell lymphopenia in WHIM syndrome","volume":"7","author":"Zehentmeier","year":"2022","journal-title":"Sci Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2200871","article-title":"Severe CD8+ T lymphopenia in WHIM syndrome caused by selective sequestration in primary immune organs","volume":"210","author":"Majumdar","year":"2023","journal-title":"J Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-527226","article-title":"A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor","volume":"123","author":"McDermott","year":"2014","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808575","article-title":"Plerixafor for the treatment of WHIM syndrome","volume":"380","author":"McDermott","year":"2019","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI164918","article-title":"A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome","volume":"133","author":"McDermott","year":"2023","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1182\/blood.2020007197","article-title":"Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome","volume":"136","author":"Dale","year":"2020","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-368084","article-title":"The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome","volume":"118","author":"McDermott","year":"2011","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022658","article-title":"A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome","volume":"144","author":"Badolato","year":"2024","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41467-023-37791-4","article-title":"WHIM Syndrome-linked CXCR4 mutations drive osteoporosis","volume":"14","author":"Anginot","year":"2023","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.83533","article-title":"Cell circuits between leukemic cells and mesenchymal stem cells block lymphopoiesis by activating lymphotoxin beta receptor signaling","volume":"12","author":"Feng","year":"2023","journal-title":"Elife"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201445245","article-title":"CXCR4 antagonist AMD3100 redistributes leukocytes from primary immune organs to secondary immune organs, lung, and blood in mice","volume":"45","author":"Liu","year":"2015","journal-title":"Eur J Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s42003-021-02070-9","article-title":"Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization","volume":"4","author":"Jorgensen","year":"2021","journal-title":"Commun Biol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/imr.12719","article-title":"WHIM syndrome: Immunopathogenesis, treatment and cure strategies","volume":"287","author":"McDermott","year":"2019","journal-title":"Immunol Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(03)00263-2","article-title":"Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence","volume":"19","author":"Martin","year":"2003","journal-title":"Immunity"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199709000-00007","article-title":"Clinical features of myelokathexis and treatment with hematopoietic cytokines: a case report of two patients and review of the literature","volume":"19","author":"Hord","year":"1997","journal-title":"J Pediatr Hematol Oncol"},{"key":"B32","article-title":"Assessment of lymphocyte subpopulations in blood: results of a phase 3 trial in WHIM syndrome","volume-title":"Presented at American Society of Pediatric Hematology and Oncology (ASPHO) Conference; April 3-6; Seattle, Washington, USA","author":"Badolato","year":""},{"key":"B33","unstructured":"Washington, DC, USA\n          American Academy of Allergy Asthma and Immunology (AAAAI 2024\n          Results of a Phase 3 Trial of an Oral CXCR4 Antagonist, Mavorixafor, for the Treatment of Participants With WHIM Syndrome: Investigational Assessment of Lymphocyte Subpopulations in Peripheral Blood\n          \n          2024"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1468823\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T06:10:30Z","timestamp":1731305430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1468823\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2024.1468823"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1468823","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"article-number":"1468823"}}